|1.||Lopera, Francisco: 20 articles (03/2015 - 05/2003)|
|2.||Sisodia, Sangram S: 10 articles (03/2014 - 07/2004)|
|3.||Fraser, P E: 8 articles (05/2015 - 05/2000)|
|4.||Schofield, Peter R: 8 articles (01/2015 - 04/2002)|
|5.||Larner, A J: 8 articles (01/2013 - 05/2003)|
|6.||Elder, Gregory A: 8 articles (01/2012 - 06/2002)|
|7.||Halliday, Glenda M: 8 articles (05/2010 - 04/2002)|
|8.||Mattson, Mark P: 8 articles (01/2010 - 05/2002)|
|9.||Cruts, M: 8 articles (08/2004 - 02/2000)|
|10.||Reiman, Eric M: 7 articles (03/2015 - 12/2012)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2011 - "Comparison of presenilin 1 and sporadic Alzheimer's disease groups revealed significantly greater thalamic retention in the presenilin 1 group and significantly greater frontotemporal retention in the sporadic Alzheimer's disease group. "
11/01/2015 - "A Study On Cytogenetic And Molecular Analysis Of Presenilin 1 (Ps1) Gene In Alzheimer's Disease."
01/01/2015 - "A large, genetically-isolated community in Antioquia, Colombia, with early-onset familial Alzheimer's disease due to a presenilin-1 mutation is ideally suited for the study of molecular mechanisms of AD, and hence accelerate the discovery of new or alternative treatment approaches. "
06/01/2014 - "We capitalized on longitudinal data collected from 1995 to 2010 from cognitively unimpaired presenilin 1 (PSEN1) E280A mutation carriers from the world's largest known early-onset autosomal dominant Alzheimer's disease kindred to identify a composite cognitive test with the greatest statistical power to track preclinical Alzheimer's disease decline and estimate the number of carriers age 30 years and older needed to detect a treatment effect in the Alzheimer's Prevention Initiative's (API) preclinical Alzheimer's disease treatment trial. "
07/01/2011 - "In a recent study, we provide evidence that specific transcript variants (TVs) of ubiquilin-1, which are genetically and functionally associated to Alzheimer's disease (AD), regulate proteasomal and aggresomal targeting of presenilin-1 (PS1), a key player in AD pathogenesis. "
05/01/2009 - "7ND expressed in APP/presenilin-1 (APP/PS1) bigenic mice reduced astro/microgliosis, beta-amyloidosis, including suppression of both fibrillar and oligomer Abeta accumulation, and improved spatial learning. "
04/01/2013 - "The current study, although small-scale, suggests increased DKI metrics, in the absence of alterations in diffusion tensor imaging metrics in the cortex and thalamus of APP/presenilin 1 mice with established amyloidosis. "
02/01/2013 - "Our current study extended our previous findings by examining cognition via (1) the rotarod test, (2) a 2-day version of the radial-arm water maze test, and (3) a subsequent observation in an open pool platform test to characterize the effects of monthly peripheral HUCBC infusion (1×10(6) cells/μL) into the transgenic PSAPP mouse model of cerebral amyloidosis (bearing mutant human APP and presenilin-1 transgenes) from 6 to 12 months of age. "
08/01/2007 - "We analyzed the relation between the mutation of presenilin-1 (PS-1) and the pathological features of beta-amyloidosis and alpha-synucleinopathy. "
01/01/2007 - "BACE1 and mutated presenilin-1 differently modulate Abeta40 and Abeta42 levels and cerebral amyloidosis in APPDutch transgenic mice."
|3.||Memory Disorders (Memory Loss)
04/01/2012 - "Val97Leu mutant presenilin-1 induces tau hyperphosphorylation and spatial memory deficit in mice and the underlying mechanisms."
11/01/2001 - "Our group has demonstrated that vaccination of a doubly transgenic mouse model (expressing mutant APP and presenilin-1) with the Abeta 1-42 peptide protects these mice from the memory deficits they would ordinarily develop. "
04/01/2012 - "Our data demonstrated that human Val97Leu mutant presenilin-1 causes spatial memory deficit in mice and increases tau phosphorylation level in glycogen synthase kinase-3-dependent manner."
01/01/2004 - "Mice transgenic for mutated forms of the amyloid precursor protein (APP) plus presenilin-1 (PS1) genes (APP + PS1 mice) gradually develop memory deficits which correlate with the extent of amyloid deposition. "
06/01/2012 - "Remarkably, XD4 also attenuated memory deficits in β-amyloid precursor protein/presenilin 1 (APPswe/PS1dE9) transgenic mice, and reduced amyloid plaque burden and Aβ40/42 levels. "
05/15/2010 - "AEA increased presenilin 1 expression and recruitment into the gamma-secretase complex, whereas 2-AG increased expression and recruitment of presenilin 2. The development of novel therapeutic strategies aimed at modulating the endocannabinoid system or mimicking the mode of action of AEA on Notch signaling pathways would prove beneficial for cholangiocarcinoma management."
06/08/2001 - "This study examined the effects of overexpression of presenilin-1 wild-type (PS1wt) or mutant L286V (PS1m) in human neuroblastoma SH-SY5Y cells on signal transduction systems. "
01/30/2007 - "[The effect of two newly Chinese presenilin-1 mutations on the sensitivity to trophic factor withdrawal in human neuroblastoma cells]."
11/01/2006 - "Morphological change by overexpression of D385A dominant negative presenilin 1 in human neuroblastoma SH-SY5Y cells."
10/02/2006 - "Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells."
08/27/2002 - "Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y."
|1.||Amyloid (Amyloid Fibrils)
|3.||Amyloid Precursor Protein Secretases (beta-Secretase)
|4.||ferulic acid (sodium ferulate)
|6.||Apolipoprotein A-I (Apolipoprotein A1)
|7.||Flavin-Adenine Dinucleotide (FAD)
|9.||Proteins (Proteins, Gene)
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)